ASCENTAGE PHARMA GROUP INTERNATIONAL business relationships

Companies named in ASCENTAGE PHARMA GROUP INTERNATIONAL’s 20-F filed 2026-04-29, and public companies whose annual reports name ASCENTAGE PHARMA GROUP INTERNATIONAL. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.

Open on the map Full AI visibility profile

AEO visibility: 4.7 / 10
AI naming: 26 / 100
Agent readiness: 25 / 100
AI adoption: 0 / 100

Named in ASCENTAGE PHARMA GROUP INTERNATIONAL’s annual report 6

TAKEDA PHARMACEUTICAL CO LTD (TAK)Customer7.7
“In addition, in June 2024, we issued and sold to Takeda 24,307,322 ordinary shares, or the Takeda Shares, for an aggregate” SEC filing
TAKEDA PHARMACEUTICAL CO LTD (TAK)Licensor7.7
“to Takeda an exclusive option to enter into an exclusive license agreement, under which Takeda would have the exclusive right (even as” SEC filing
ASTRAZENECA PLC (AZN)Partner7.7
“a collaboration and license agreement with Innovent and clinical collaboration agreements with AstraZeneca, Merck, and Pfizer, and research” SEC filing
Merck & Co., Inc. (MRK)Partner7.7
“with unresectable or metastatic melanoma (in collaboration with Merck & Co.) or other” SEC filing
PFIZER INC (PFE)Partner7.7
“a collaboration and license agreement with Innovent and clinical collaboration agreements with AstraZeneca, Merck, and Pfizer, and research” SEC filing
Innovent Biologics (IVBXF)Licensor-
“| Collaboration and License Agreement between Ascentage Pharma Group Corp Limited, Guangzhou Healthquest Pharma Corp Limited, and Innovent Biologics (Suzhou) Co., LTD, Dated as of July 14, 2021 |” SEC filing

Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.